<DOC>
	<DOCNO>NCT01008956</DOCNO>
	<brief_summary>This study design characterize safety immunogenicity ' pandemic influenza ( H1N1 ) candidate vaccine GSK2340274A adult 18 64 year age .</brief_summary>
	<brief_title>Safety Immune Response One-Dose Candidate H1N1 Influenza Vaccine GSK2340274A Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Indian male female adult 18 64 year age time first vaccination , inclusive . Written inform consent obtain subject Good general health assess medical history physical examination . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device ( i.e. , commonuse phone serve multiple room apartment ) Subjects investigator believe comply requirement protocol . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Medical history physicianconfirmed infection A/California/7/2009 ( H1N1 ) vlike virus . Previous vaccination time A/California/7/2009 ( H1N1 ) vlike virus vaccine . Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence temperature &gt; = 38.0ºC ( &gt; =100.4ºF ) route method , acute symptom great `` mild '' severity schedule date first vaccination . NOTE : The subject may vaccinate later date , provide symptom resolve , vaccination occurs within window specify protocol , eligibility criterion continue satisfy . Presence significant acute chronic , uncontrolled medical psychiatric illness ( `` uncontrolled '' define require institution new medical surgical treatment significant alteration dose ongoing medication uncontrolled symptom , illness manifestation drug toxicity within 3 month precede receipt study vaccine ) . Diagnosed cancer , treatment cancer within 3 year . Persons history cancer diseasefree without treatment 3 year eligible . Persons history histologicallyconfirmed basal cell carcinoma skin successfully treat local excision accept may enrol , histologic type skin cancer exclusionary . Women diseasefree 3 year treatment breast cancer receive longterm prophylactic tamoxifen except may enrol . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ( laboratory testing require ) . Chronic administration ( defined 14 day total ) immunosuppressant immune modify drug within 6 month study enrolment plan administration study period . For corticosteroid , mean dose equivalent 10 mg/day prednisone equivalent administer &gt; 2 week . Topical , intraarticular inhale topical steroid allow . Receipt immunoglobulins and/or blood product within 3 month study enrolment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine . With exception seasonal influenza vaccination , administration vaccine within 30 day vaccination . Seasonal influenza vaccine may administer 14 day prior study vaccination . Planned administration vaccine foreseen study protocol vaccination blood sample Day 21 include seasonal influenza vaccine monovalent pandemic H1N1 vaccine study vaccine . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede receipt study vaccine , plan use study period . Any known suspected allergy constituent influenza vaccine component use manufacturing process study vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( ßhCG ) test result prior time vaccination . Lactating nursing female . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>H1N1</keyword>
	<keyword>Pandemic</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2340274A</keyword>
</DOC>